Host Cell Protein (HCP) residuals refer to protein components derived from the production host cell line present in biopharmaceutical products. These mainly include structural proteins and secretory proteins of the host cells. Due to the diverse nature of these proteins and their significantly different physicochemical properties (such as isoelectric points, hydrophobicity, and relative molecular mass), their residual presence in biopharmaceuticals can have critical effects on product quality and safety.
As process-related impurities, HCP residuals can trigger immune responses, affect the efficacy of the biopharmaceuticals, and even lead to hypersensitivity or other adverse reactions. Therefore, the residual amount of HCP needs to be strictly controlled, making it a critical quality attribute (CQA) in pharmaceutical quality control.
With the continuous development of biotechnology and the globalization of biopharmaceutical production, more biopharmaceuticals are being produced through cell culture methods. To enhance product quality control levels, it has become an inevitable trend to develop suitable residual host cell protein analysis methods. Improvements in these methods not only help to enhance the safety of biopharmaceuticals but also ensure their efficacy.
Among the various residual host cell protein analysis methods, Enzyme-Linked Immunosorbent Assay (ELISA) is widely regarded as the gold standard for residual host cell protein analysis. ELISA has the advantages of being simple to operate, rapid, and high-throughput, making it suitable for large-scale detection.
However, due to the vast variety of host cell proteins and their reduced quantity as purification progresses, the diversity of HCP antigens and corresponding antibodies poses challenges for the validation of HCP immunoassay methods. For the validation of intermediate samples, key indicators include method accuracy (e.g., spike recovery), dilution linearity, and precision; for final products, the analysis should involve aspects such as accuracy, precision, dilution linearity, specificity, and quantitation limits.
Although ELISA can effectively quantify the total HCP content in a drug, this method still has some limitations. For instance, the antibody coverage in ELISA kits usually only reaches about 50%-80%, and therefore cannot cover all HCP types. Furthermore, ELISA can only measure the total amount and cannot provide specific types and amounts of each HCP. Therefore, a comprehensive analysis of HCP residuals may require the integration of other technologies, such as mass spectrometry, to further improve the comprehensiveness and accuracy of the analysis.
With technological advancements, the development of more comprehensive and sensitive residual host cell protein analysis methods is becoming a primary focus for the future. Combining multiple analytical technologies (such as ELISA and mass spectrometry) will help to better understand the types and quantities of HCP, thereby further enhancing the safety and efficacy of biopharmaceuticals.
Additionally, to accommodate the globalization trend of bio-information, residual host cell protein analysis methods need continuous optimization to meet the regulatory requirements of different countries and regions.
info@shentekbio.com 
English
